Cabaletta Bio Files 8-K on Operations and Financials
Ticker: CABA · Form: 8-K · Filed: May 15, 2024 · CIK: 1759138
Sentiment: neutral
Topics: financial-reporting, operations, disclosure
TL;DR
Cabaletta Bio dropped an 8-K detailing its financials and operations. Check it out.
AI Summary
Cabaletta Bio, Inc. filed an 8-K on May 15, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Delaware and headquartered in Philadelphia, PA.
Why It Matters
This 8-K filing provides investors with crucial updates on Cabaletta Bio's operational performance and financial standing, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine 8-K filing providing standard corporate disclosures and financial information.
Key Players & Entities
- Cabaletta Bio, Inc. (company) — Registrant
- May 15, 2024 (date) — Date of Report
- Philadelphia, PA (location) — Principal executive offices location
- Delaware (location) — State of incorporation
FAQ
What specific financial information is being disclosed in this 8-K?
This 8-K filing indicates that it includes 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', suggesting a disclosure of financial performance and related documents.
What is the primary purpose of this 8-K filing for Cabaletta Bio?
The primary purpose is to report on the company's 'Results of Operations and Financial Condition', as well as to provide 'Regulation FD Disclosure' and 'Financial Statements and Exhibits'.
When was this 8-K report filed?
This 8-K report was filed on May 15, 2024.
Where is Cabaletta Bio, Inc. headquartered?
Cabaletta Bio, Inc. is headquartered at 2929 Arch Street, Suite 600, Philadelphia, PA 19104.
What is the SIC code for Cabaletta Bio, Inc.?
The Standard Industrial Classification (SIC) code for Cabaletta Bio, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 675 words · 3 min read · ~2 pages · Grade level 9.8 · Accepted 2024-05-15 07:04:38
Key Financial Figures
- $0.00001 — ich Registered Common Stock, par value $0.00001 per share CABA The Nasdaq Global Se
Filing Documents
- d106913d8k.htm (8-K) — 27KB
- d106913dex991.htm (EX-99.1) — 49KB
- d106913dex992.htm (EX-99.2) — 37KB
- g106913ex99_2p10g1.jpg (GRAPHIC) — 381KB
- g106913ex99_2p11g1.jpg (GRAPHIC) — 411KB
- g106913ex99_2p12g1.jpg (GRAPHIC) — 403KB
- g106913ex99_2p13g1.jpg (GRAPHIC) — 432KB
- g106913ex99_2p14g1.jpg (GRAPHIC) — 424KB
- g106913ex99_2p15g1.jpg (GRAPHIC) — 252KB
- g106913ex99_2p16g1.jpg (GRAPHIC) — 429KB
- g106913ex99_2p17g1.jpg (GRAPHIC) — 117KB
- g106913ex99_2p18g1.jpg (GRAPHIC) — 362KB
- g106913ex99_2p19g1.jpg (GRAPHIC) — 375KB
- g106913ex99_2p1g1.jpg (GRAPHIC) — 224KB
- g106913ex99_2p20g1.jpg (GRAPHIC) — 222KB
- g106913ex99_2p2g1.jpg (GRAPHIC) — 899KB
- g106913ex99_2p3g1.jpg (GRAPHIC) — 191KB
- g106913ex99_2p4g1.jpg (GRAPHIC) — 375KB
- g106913ex99_2p5g1.jpg (GRAPHIC) — 385KB
- g106913ex99_2p6g1.jpg (GRAPHIC) — 163KB
- g106913ex99_2p7g1.jpg (GRAPHIC) — 436KB
- g106913ex99_2p8g1.jpg (GRAPHIC) — 395KB
- g106913ex99_2p9g1.jpg (GRAPHIC) — 380KB
- g106913g0514222831811.jpg (GRAPHIC) — 4KB
- 0001193125-24-138874.txt ( ) — 10260KB
- caba-20240515.xsd (EX-101.SCH) — 3KB
- caba-20240515_lab.xml (EX-101.LAB) — 18KB
- caba-20240515_pre.xml (EX-101.PRE) — 11KB
- d106913d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release issued by the registrant on May 15, 2024, furnished herewith. 99.2 Cabaletta Bio, Inc. Corporate Presentation, dated May 15, 2024, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CABALETTA BIO, INC. Date: May 15, 2024 By: /s/ Steven Nichtberger Steven Nichtberger, M.D. President and Chief Executive Officer